. 2013 Feb 21;42(4):972–981. doi: 10.1183/09031936.00165712

Table 3– Weighted mean 0–24-h forced expiratory volume in 1 s (FEV₁) on day 28, trough forced vital capacity (FVC) on day 29 and salbutamol use during the study.

	Weighted mean FEV₁ (0–24 h) on day 28		Trough FVC on day 29		Salbutamol use
	Subjects	Difference mL	Subjects	Difference mL	Subjects	Difference mL
Placebo	34		71		78
Salmeterol	19	85 (-21–191)^#	43	120 (-3–244)^#	43	-0.39 (-0.73– -0.05)*
GSK961081
Twice daily
100 μg	22	226 (125–327)***	47	310 (190–430)***	50	-0.57 (-0.89– -0.25)***
200 μg	21	325 (222–428)***	46	374 (253–496)***	48	-0.56 (-0.88– -0.23)***
400 μg	24	307 (209–405)***	49	328 (210–446)***	52	-0.74 (-1.05– -0.42)***
Once daily
100 μg	18	246 (139–353)***	45	153 (31–275)*	48	-0.45 (-0.78– -0.12)**
400 μg	18	300 (192–407)***	41	310 (185–435)***	45	-0.65 (-0.99– -0.32)***
800 μg	23	335 (236–434)***	48	381 (261–500)***	51	-0.62 (-0.94– -0.30)***

Data are presented as n or least squares mean (95% CI). Inference between salmeterol and placebo was part of a post hoc analysis. Least squares means were adjusted for age, sex, smoking status, reversibility stratum, overnight site stratum, concurrent inhaled corticosteroid use, baseline and treatment. ^#: not significant; *: p<0.05; **: p<0.01; ***: p<0.001.

Table 3– Weighted mean 0–24-h forced expiratory volume in 1 s (FEV1) on day 28, trough forced vital capacity (FVC) on day 29 and salbutamol use during the study.

Table 3– Weighted mean 0–24-h forced expiratory volume in 1 s (FEV₁) on day 28, trough forced vital capacity (FVC) on day 29 and salbutamol use during the study.